Transthyretin Amyloid Cardiomyopathy Clinical Trial
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Summary
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.
Full Description
This is a multicenter, open-label, Phase 3 study in up to approximately 1400 participants. Eligible participants will receive eplontersen once every 4 weeks for up to 36 months or 6 months after eplontersen is approved and available in the site's country, whichever occurs first. Participants will also receive daily supplemental doses of the recommended daily allowance (RDA) of vitamin A. This study will consist of the following periods: less than or equal to (≤) 10-week screening assessment period, up to 36-month treatment period, and up to 6-month post-treatment evaluation period.
Eligibility Criteria
Inclusion Criteria:
Satisfactory completion of Treatment Period and the End of Treatment Visit of the Index Study (ION-682884-CS2) OR diagnosis of ATTR-CM and satisfactory participation on ISIS 420915- CS101 study as judged by the Investigator and Sponsor.
Investigator is willing to treat the participant with open-label eplontersen.
Willingness to adhere to vitamin A supplementation per protocol.
Exclusion Criteria:
Permanently discontinued study drug administration while participating in the Index Study (ION 682884-CS2) or IST (ISIS 420915-CS101 Study).
Have any new condition or worsening of an existing condition that in the opinion of the Investigator or Sponsor would make the participant unsuitable for enrolment, or which could interfere with the participant participating in or completing the study, including the need for treatment with medications disallowed in the Index Study.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 59 Locations for this study
Scottsdale Arizona, 85259, United States
Beverly Hills California, 90211, United States
La Jolla California, 92037, United States
Aurora Colorado, 80045, United States
Washington District of Columbia, 20010, United States
Weston Florida, 33331, United States
Atlanta Georgia, 30309, United States
Fayetteville Georgia, 30214, United States
Chicago Illinois, 60611, United States
Indianapolis Indiana, 46202, United States
Kansas City Kansas, 66160, United States
Baltimore Maryland, 21201, United States
Boston Massachusetts, 02114, United States
Boston Massachusetts, 02118, United States
Rochester Minnesota, 55905, United States
Saint Louis Missouri, 63110, United States
New York New York, 10016, United States
New York New York, 10021, United States
New York New York, 10034, United States
Chapel Hill North Carolina, 27599, United States
Durham North Carolina, 27710, United States
Cleveland Ohio, 44195, United States
Columbus Ohio, 43210, United States
Portland Oregon, 97239, United States
Philadelphia Pennsylvania, 19104, United States
Nashville Tennessee, 37232, United States
Dallas Texas, 75390, United States
Salt Lake City Utah, 84112, United States
Richmond Virginia, 23298, United States
Seattle Washington, 98195, United States
Murdoch West Australia, 6150, Australia
Joondalup Western Australia, 6027, Australia
Liverpool , 2170, Australia
Graz , 8036, Austria
Innsbruck , 6020, Austria
Brugge , 8000, Belgium
Calgary Alberta, T2N 4, Canada
London Ontario, N6A 5, Canada
Montréal Quebec, H2X 0, Canada
La Roche-sur-Yon , 85925, France
Nantes , 44093, France
Pessac , 33604, France
Homburg , 66421, Germany
Münster , 48149, Germany
Würzburg , 97078, Germany
Athens , 115 2, Greece
Haifa , 31096, Israel
Rehovot , 76610, Israel
Firenze , 50134, Italy
Pavia , 27100, Italy
Guimarães , 4835-, Portugal
Porto , 4099-, Portugal
Porto , 4200-, Portugal
Barcelona , 08035, Spain
Majadahonda , 28222, Spain
Murcia , 30120, Spain
Göteborg , 413 4, Sweden
Skellefteå , 931 8, Sweden
London , SE1 1, United Kingdom
How clear is this clinincal trial information?